Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Randall

Showing results (411-420 of 456) with videos related to

Pageof 46
Sort By:
Plos One|May 6, 2020
Changes of Fusarium oxysporum f.sp. lactucae levels and soil microbial community during soil biosolarization using chitin as soil amendmentTara E Randall, Jesus D Fernandez-Bayo, Duff R Harrold, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 26, 2015
Oligoribonuclease is a central feature of cyclic diguanylate signaling in Pseudomonas aeruginosaDorit Cohen, Undine Mechold, Hadas Nevenzal, et al.
Antiviral Research|November 4, 2015
The lipid moiety of brincidofovir is required for in vitro antiviral activity against Ebola virusLaura K McMullan, Mike Flint, Julie Dyall, et al.
Gynecologic Oncology|October 4, 2011
Cervical cancer survival for patients referred to a tertiary care center in KentuckyLeigh G Seamon, Rebecca L Tarrant, Steve T Fleming, et al.
Antimicrobial Agents and Chemotherapy|May 5, 2010
Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIVE Randall Lanier, Roger G Ptak, Bernhard M Lampert, et al.
Plos Medicine|August 1, 2008
Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naïve populations and associate with reduced treatment efficacyJeffrey A Johnson, Jin-Fen Li, Xierong Wei, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 29, 2005
Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infectionThomas B Campbell, Nancy S Shulman, Steven C Johnson, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 9, 2004
Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adultsEdwin DeJesus, Gisela Herrera, Eugenio Teofilo, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 9, 2013
STAT2 deficiency and susceptibility to viral illness in humansSophie Hambleton, Stephen Goodbourn, Dan F Young, et al.
Journal of Paediatrics and Child Health|August 11, 2018
Evaluation of national guidelines for bronchiolitis: AGREEments and controversiesDiana Cavaye, Daniel P Roberts, Gemma L Saravanos, et al.
Pageof 46

Showing results (411-420 of 456) with videos related to

Sort By:
Pageof 46
Plos One|May 6, 2020
Changes of Fusarium oxysporum f.sp. lactucae levels and soil microbial community during soil biosolarization using chitin as soil amendmentTara E Randall, Jesus D Fernandez-Bayo, Duff R Harrold, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 26, 2015
Oligoribonuclease is a central feature of cyclic diguanylate signaling in Pseudomonas aeruginosaDorit Cohen, Undine Mechold, Hadas Nevenzal, et al.
Antiviral Research|November 4, 2015
The lipid moiety of brincidofovir is required for in vitro antiviral activity against Ebola virusLaura K McMullan, Mike Flint, Julie Dyall, et al.
Gynecologic Oncology|October 4, 2011
Cervical cancer survival for patients referred to a tertiary care center in KentuckyLeigh G Seamon, Rebecca L Tarrant, Steve T Fleming, et al.
Antimicrobial Agents and Chemotherapy|May 5, 2010
Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIVE Randall Lanier, Roger G Ptak, Bernhard M Lampert, et al.
Plos Medicine|August 1, 2008
Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naïve populations and associate with reduced treatment efficacyJeffrey A Johnson, Jin-Fen Li, Xierong Wei, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 29, 2005
Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infectionThomas B Campbell, Nancy S Shulman, Steven C Johnson, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 9, 2004
Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adultsEdwin DeJesus, Gisela Herrera, Eugenio Teofilo, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 9, 2013
STAT2 deficiency and susceptibility to viral illness in humansSophie Hambleton, Stephen Goodbourn, Dan F Young, et al.
Journal of Paediatrics and Child Health|August 11, 2018
Evaluation of national guidelines for bronchiolitis: AGREEments and controversiesDiana Cavaye, Daniel P Roberts, Gemma L Saravanos, et al.
Pageof 46